Download PDF
CC BY-NC-ND 4.0 · Z Gastroenterol 2023; 61(10): 1385-1393
DOI: 10.1055/a-2000-5705
Kasuistik

Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab – Differences and Similarities in Comparison to “endogenous” autoimmune Type A Gastritis and a review of literature

Immun-vermittelte Gastritis bei einem Patienten mit metastasiertem Bronchialkarzinom in Folge einer Therapie mit dem Immun Checkpoint Inhibitor Pembrolizumab – Unterschiede und Ähnlichkeiten im Vergleich zur „endogenen“ autoimmun-vermittelten Typ A Gastritis und eine Literaturübersicht
Miriam Eva Ecker 
1   Gastroenterology, Endocrinology, Diabetology and General Medicine, Klinikum Kassel GmbH, Kassel, Germany (Ringgold ID: RIN60021)
,
Helgard Weckauf
2   Pathology, Klinikum Kassel GmbH, Kassel, Germany (Ringgold ID: RIN60021)
,
Sandra Tebbe
3   Private Practice for Haematology and Oncology, Kassel, Germany
,
Frank Schuppert
1   Gastroenterology, Endocrinology, Diabetology and General Medicine, Klinikum Kassel GmbH, Kassel, Germany (Ringgold ID: RIN60021)
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Immune checkpoint inhibitors are increasingly used in advanced malignant diseases and are well-known for their good results. With the blockade of immune checkpoints, the probability of immune-related adverse events is also increased.

We present a 54-year-old female patient with advanced NSCLC. She was treated with pembrolizumab and developed a stable disease under therapy. After six cycles, she presented with massive epigastric pain to our emergency department. Gastroscopy showed severe erosive-fibrinous pangastritis without the involvement of the esophagus, duodenum, or other immune-related adverse effects. Histology showed the complete destruction of the gastric mucosa. We concluded an immune-mediated gastritis by pembrolizumab, after the exclusion of other differential diagnoses.

Despite treatment with prednisolone and marked improvement of her symptoms, the mucosa was never fully reconstituted into a healthy mucosa.

Furthermore, we collected published reports of similar cases and conducted a comparison with features of a typical, endogenous type A gastritis to highlight similarities and differences.

Zusammenfassung

Immun-Checkpoint-Inhibitoren finden immer häufiger Anwendung in der Therapie von fortgeschrittenen Tumorleiden und sind inzwischen bekannt für ihre Effektivität. Bedingt durch ihren Wirkmechanismus kommt es allerdings auch zu immunvermittelten Nebenwirkungen.

Wir präsentieren den Fall einer 54-jährigen Patientin, die bei fortgeschrittenem NSCLC mit Pembrolizumab behandelt wurde. Darunter wurde eine stable disease erreicht. Nach 6 Zyklen Pembrolizumab stellte sie sich mit stärksten epigastrischen Schmerzen in unserer Notaufnahme vor. In der Gastroskopie zeigte sich eine fibrinös-erosive Pangastritis, ohne jegliche Beteiligung von Ösophagus und Duodenum oder eines anderen Organsystems. Die histologische Untersuchung des gastralen Gewebes zeigte eine vollständige Destruktion des Epithels. Nach Ausschluss einer klassischen Typ A-, B- oder C-Gastritis, schlussfolgerten wir eine immunvermittelte Gastritis durch Pembrolizumab.

Auch nach Therapie mit Prednisolon und trotz deutlicher klinischer Befundbesserung rekonstituierte sich die Mukosa auch nach 6 Monaten nicht mehr vollständig.

Des Weiteren führten wir eine Literaturrecherche zu publizierten Fällen ähnlicher Gastritiden unter Pembrolizumab durch und verglichen das Krankheitsbild mit der klassischen Typ A-Gastritis.

Schlüsselwörter

Immunvermittelte Gastritis - Autoimmungastritis - Typ A Gastritis - Nicht-kleinzelliges Bronchialkarzinom - Immuncheckpoint-Inhibitor - Pembrolizumab

Keywords

immune-mediated gastritis - autoimmune gastritis - type A gastritis - non-small cell lung cancer - immune checkpoint inhibitor - pembrolizumab


Publication History

Received: 07 November 2022

Accepted after revision: 13 December 2022

Article published online:
24 March 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Dougan M, Luoma AM, Dougan SK. et al. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021; 184 (06) 1575-1588 DOI: 10.1016/j.cell.2021.02.011. (PMID: 33675691)
    CrossrefPubMedGoogle Scholar
  • 2 Reck M, Rodriguez-Abreu D, Robinson AG. et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. New England Journal of Medicine 2016; 375 (19) 1823-1833 DOI: 10.1056/NEJMoa1606774. (PMID: 27718847)
    CrossrefPubMedGoogle Scholar
  • 3 Dougan M, Dougan SK. Targeting Immunotherapy to the Tumor Microenvironment. J Cell Biochem 2017; 118 (10) 3049-3054 DOI: 10.1002/jcb.26005. (PMID: 28332219)
    CrossrefPubMedGoogle Scholar
  • 4 Teufel A, Zhan T, Hartel N. et al. Management of immune related adverse events induced by immune checkpoint inhibition. Cancer Letters 2019; 456: 80-87 DOI: 10.1016/j.canlet.2019.04.018. (PMID: 31051213)
    CrossrefPubMedGoogle Scholar
  • 5 Paparoupa M, Stupperich S, Goerg-Reifenberg L. et al. Successful Treatment of an Immune-Mediated Colitis Induced by Checkpoint Inhibitor Therapy in a Patient with Advanced Melanoma. Case Rep Gastroenterol 2020; 14 (03) 554-560
    CrossrefPubMedGoogle Scholar
  • 6 Hartmann A, Paparoupa M, Volkmer BG. et al. Autoimmune hypophysitis secondary to therapy with immune checkpoint inhibitors: Four cases describing the clinical heterogeneity of central endocrine dysfunction. J Oncol Pharm Pract 2020; 26 (07) 1774-1779
    CrossrefPubMedGoogle Scholar
  • 7 Wills B, Brahmer JR, Naidoo J. Treatment of Complications from Immune Checkpoint Inhibition in Patients with Lung Cancer. Cur Treat Options Oncol 2018; 19 (09) 46
    CrossrefPubMedGoogle Scholar
  • 8 Steinbuss G, Kriegsmann K, Kriegsmann M. Identification of Gastritis Subtypes by Convolutional Neuronal Networks on Histological Images of Antrum and Corpus Biopsies. Int J Mol Sci 2020; 21 (18) 11 DOI: 10.3390/ijms21186652. (PMID: 32932860)
    CrossrefPubMedGoogle Scholar
  • 9 Kamada T, Maruyama Y, Monobe Y. et al. Endoscopic features and clinical importance of autoimmune gastritis. Dig Endosc 2022; 34 (04) 700-713 DOI: 10.1111/den.14175. (PMID: 34674318)
    CrossrefPubMedGoogle Scholar
  • 10 Lahner E, Norman GL, Severi C. et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol 2009; 104 (08) 2071-2079
    CrossrefPubMedGoogle Scholar
  • 11 Pimentel-Nunes P, Libânio D, Marcos-Pinto R. et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019; 51 (04) 365-388 DOI: 10.1055/a-0859-1883. (PMID: 30841008)
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Shah SC, Piazuelo MB, Kuipers EJ. et al. AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review. Gastroenterology 2021; 161 (04) 1325-1332.e7
    CrossrefPubMedGoogle Scholar
  • 13 Hayama N, Ihara H, Honma Y. et al. Severe gastritis due to pembrolizumab treatment in a lung cancer patient Respirol Case Rep: © 2020 The Authors. Respirology Case Reports published by John Wiley & Sons Australia, Ltd on behalf of The Asian Pacific Society of Respirology. 2020
    PubMedGoogle Scholar
  • 14 Saito K, Ozono D, Nagumo H. et al. Temporal observation of endoscopic and histological findings of gastritis after administration of an immune checkpoint inhibitor: a case report. Clin J Gastroenterol 2022; 15 (02) 368-373 DOI: 10.1007/s12328-021-01582-5. (PMID: 34985687)
    CrossrefPubMedGoogle Scholar
  • 15 Nasser R, Fisher Y, Klein A. Gastrointestinal: Severe gastritis with complete gastric mucosal sloughing. J Gastroenterol Hepatol 2021; 36 (10) 2639 DOI: 10.1111/jgh.15427. (PMID: 33624341)
    CrossrefPubMedGoogle Scholar
  • 16 Omotehara S, Nishida M, Yamanashi K. et al. A case of immune checkpoint inhibitor- associated gastroenteritis detected by ultrasonography. J Clin Ultrasound 2021; 49 (06) 605-609 DOI: 10.1002/jcu.22975. (PMID: 33580597)
    CrossrefPubMedGoogle Scholar
  • 17 Okubo Y, Hosotani K, Taniguchi Y. et al. Gastrointestinal: Recurrence of pembrolizumab- induced severe gastritis after tapering steroid therapy. J Gastroenterol Hepatol 2021; 36 (03) 586 DOI: 10.1111/jgh.15248. (PMID: 32945040)
    CrossrefPubMedGoogle Scholar
  • 18 Vandepapelière J, Siplet J, Libbrecht L. et al. Auto-immune gastritis induced by pembrolizumab, an anti-PD-1, in a melanoma patient. Acta Gastroenterol Belg 2020; 83 (03) 482-484 (PMID: 33094598)
    PubMedGoogle Scholar
  • 19 Kim H, Ha SY, Kim J. et al. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Curr Oncol 2020; 27 (04) e436-e39
    CrossrefPubMedGoogle Scholar
  • 20 Elmasry M, Dong B, Rios C. et al. Delayed hemorrhagic gastritis caused by immunotherapy in a patient With metastatic melanoma. Am J Med Sci 2022; DOI: 10.1016/j.amjms.2022.02.010.
    CrossrefPubMedGoogle Scholar
  • 21 Cinnor B, Crossman H, Kaplan J. et al. First Reported Case of Pembrolizumab-Induced Immune Mediated Hemorrhagic Gastritis. Gastroenterology 2017; 52 (05) S891
    CrossrefPubMedGoogle Scholar
  • 22 Liu WT, Li YF, Hsieh TY. Unusual severe gastritis and gastric ulcers caused by pembrolizumab. Journal Postgrad Med 2022; 68 (01) 38-40 DOI: 10.4103/jpgm.JPGM_1132_20. (PMID: 34121670)
    CrossrefPubMedGoogle Scholar
  • 23 Rao BB, Robertson S, Philpott J. Checkpoint Inhibitor-Induced Hemorrhagic Gastritis with Pembrolizumab. Am J Gastroenterol 2019; 114 (02) 196 DOI: 10.1038/s41395-018-0366-3. (PMID: 30353060)
    CrossrefPubMedGoogle Scholar
  • 24 Gaffuri P, Espeli V, Fulciniti F. et al. Immune-related acute and lymphocytic gastritis in a patient with metastatic melanoma treated with pembrolizumab immunotherapy. Pathologica 2019; 111 (03) 92-97
    CrossrefPubMedGoogle Scholar
  • 25 Yip RHL, Lee LH, Schaeffer DF. et al. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma. Melanoma Res 2018; 28 (06) 645-647
    CrossrefPubMedGoogle Scholar
  • 26 Lu J, Firpi-Morell RJ, Dang LH. et al. An Unusual Case of Gastritis in One Patient Receiving PD-1 Blocking Therapy: Coexisting Immune-Related Gastritis and Cytomegaloviral Infection. Gastroenterol Res 2018; 11 (05) 383-387 DOI: 10.14740/gr1068w. (PMID: 30344812)
    CrossrefPubMedGoogle Scholar
  • 27 Mendo R, Figueiredo P, Mascarenhas L. Checkpoint Inhibitor-Induced Gastroduodenitis: An Unusual Manifestation. GE Port J Gastroenterol 2021; 150-152 DOI: 10.1159/000509196. (PMID: 33791404)
    CrossrefPubMedGoogle Scholar
  • 28 Carmel R. Diagnosis and management of clinical and subclinical cobalamin deficiencies: why controversies persist in the age of sensitive metabolic testing. Biochimie 2013; 95 (05) 1047-1055 DOI: 10.1016/j.biochi.2013.02.008. (PMID: 23416723)
    CrossrefPubMedGoogle Scholar
  • 29 Sawai Y, Katsuya Y, Shinozaki-Ushiku A. et al. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-alpha antibody infliximab. Drug Discov Ther 2019; 13 (03) 164-167 DOI: 10.5582/ddt.2019.01032. (PMID: 31257354)
    CrossrefPubMedGoogle Scholar